ReviewJournal of comorbidity
Physiological markers and multimorbidity: A systematic review.
Review in Journal of comorbidity. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Longitudinal Associations Between Inflammation and Multi-Dimensional Fatigue up to 2 Years After Colorectal Cancer Diagnosis.International journal of cancer · 2026Article
- The Neuro-Cardio-Renal Stress Index (NCR-SI): A Pragmatic Composite Framework for Characterizing Multisystem Burden in Multimorbid Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Protein Source, Dietary Fibre Intake, and Inflammation in Older Adults: A UK Biobank Study.Nutrients · 2025Article
- Association of inflammatory markers and multimorbidity in young adults: cross-sectional findings from the Pelotas (Brazil) birth cohort, 1993.Cadernos de saude publica · 2025Article
- Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain.Frontiers in cardiovascular medicine · 2025Article
- Molecular Morbidity Score-Can MicroRNAs Assess the Burden of Disease?International journal of molecular sciences · 2024Review
- Multi-morbidity and its association with common cancer diagnoses: a UK Biobank prospective study.BMC public health · 2023Article
- Home-built environment interventions and inflammation biomarkers: a systematic review and meta-analysis protocol.BJGP open · 2022Article
- Mapping human disease-associated enzymes into Reactome allows characterization of disease groups and their interactions.Scientific reports · 2022Article
- Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study.The Journal of infectious diseases · 2022Article
- Multimorbidity.Nature reviews. Disease primers · 2022Review
- Improving the prognostic value of multimorbidity through the integration of selected biomarkers to the comprehensive geriatric assessment: An observational retrospective monocentric study.Frontiers in medicine · 2022Article
- The Role of Extracellular Vesicles as a Shared Disease Mechanism Contributing to Multimorbidity in Patients With COPD.Frontiers in immunology · 2021Review
- A conceptual framework for characterising lifecourse determinants of multiple long-term condition multimorbidity.Journal of multimorbidity and comorbidityArticle
- Importance of Dehydroepiandrosterone Sulfate Assessment with Special Attention for Adrenal Tumours and Arterial Hypertension.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultimorbidity is the co-occurrence of two or more diseases in the same individual. One method to identify this condition at an early stage is the use of specific markers for various combinations of morbidities. Nonetheless, evidence related to physiological markers in multimorbidity is limited.
objectiveThe aim was to perform a systematic review to identify physiological markers associated with multimorbidity.
designArticles available on PubMed, Register of Controlled Trials, Academic Search Premier, CINAHL, Scopus, SocINDEX, Web of Science, LILACS, and SciELO, from their inception to May 2018, were systematically searched and reviewed. The project was registered in PROSPERO under the number CRD42017055522.
resultsThe systematic search identified 922 papers. After evaluation, 18 articles were included in the full review reporting at least one physiological marker in coexisting diseases or which are strongly associated with the presence of multimorbidity in the future. Only five of these studies examined multimorbidity in general, identifying five physiological markers associated with multimorbidity, namely, dehydroepiandrosterone sulfate (DHEAS), interleukin 6 (IL-6), C-reactive protein (CRP), lipoprotein (Lp), and cystatin C (Cyst-C).
conclusionsThere is a paucity of studies related to physiological markers in multimorbidity. DHEAS, IL-6, CRP, Lp, and Cyst-C could be the initial focus for further investigation of physiological markers related to multimorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.